New study aims to predict which patients benefit from targeted radiation for rare gut tumors

NCT ID NCT06256705

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 28 times

Summary

This study enrolls 80 people with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who are scheduled for peptide receptor radionuclide therapy (PRRT). Researchers will collect PET-MRI scans, genetic profiles, and other data before, during, and after treatment. The goal is to find early signs that predict whether PRRT is working, which could help doctors choose the best treatment for each patient in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hépato-gastro-entérologie, cancérologie digestive et assistance nutritionnelle - CHU Nantes

    ACTIVE_NOT_RECRUITING

    Nantes, 44000, France

  • Médecine nucléaire - CHU Nantes

    RECRUITING

    Nantes, 44000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Médecine nucléaire et Biophysique - Beaujon

    RECRUITING

    Clichy, 92110, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Pancréatologie et Oncologie Digestive - Beaujon

    RECRUITING

    Clichy, 92110, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Service de Médecine Nucléaire, Groupe Hospitalier Bichat-Claude Bernard

    ACTIVE_NOT_RECRUITING

    Paris, 75018, France

Conditions

Explore the condition pages connected to this study.